adenylosuccinic acid
Phase 1Small molecule
adenylosuccinic acid is one of 11 small molecule programs targeting Myopathy. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
12 competitors in Myopathy
#DrugCompanyPhaseTrials
1Viagra
VViatris Specialty LLC
Approved
Zocor
OOrganon and Co
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Mesnex
BBaxter Healthcare Corporation
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Cytoxan
BBaxter Healthcare Corporation
Approved
Dantrium
AAultman Health Foundation
Phase 3
Salbutamol
GSKPreclinical
Coenzyme Q10
MMclean Hospital
Preclinical
adenylosuccinic acid
CCure ADSSL1
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for adenylosuccinic acid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- CCure ADSSL1